Early immunotherapy may improve outcomes in new-onset refractory status epilepticus (NORSE)

Researchers have suggested that early use of immunotherapy may be beneficial in children with new-onset refractory status epilepticus (NORSE).

According to Dr Harshkumar Patel of Zydus Hospitals in Ahmedabad, India, NORSE is defined as new onset status epilepticus with no known cause in a patient with no pre-existing epilepsy or other neurological disorders. Febrile infection-related epilepsy syndrome (FIRES) is a subset of NORSE patients characterized by febrile infection between 24 hours and 2 weeks before the onset of status epilepticus.

Dr Patel and colleagues described the characteristics of children presenting with NORSE at 2 treatment centers between 2017 and 2019, and the effects of early immunotherapy in these patients.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.